This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Walgreens (WBA) Expands Access to COVID-19 Test With LabCorp
by Zacks Equity Research
Walgreens (WBA) will enable more communities to access reliable, convenient testing services as and when required with the addition of Pixel by LabCorp COVID-19 at-home collection kit.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
PacBio (PACB) Supports SickKids With Sequencing Technology
by Zacks Equity Research
PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.
Zacks.com featured highlights include AutoNation, Asbury Automotive Group, AMN Healthcare Services, Teck Resources and AGCO
by Zacks Equity Research
AutoNation, Asbury Automotive Group, AMN Healthcare Services, Teck Resources and AGCO are included in this blog.
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
Catalent's (CTLT) New Tie-Up to Provide Better Patient Access
by Zacks Equity Research
Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.
Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation
by Zacks Equity Research
Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.
AMN or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
Why AMN Healthcare Services (AMN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Lucrative Value Stocks Based on Discounted PEG to Buy Now
by Urmimala Biswas
Here are five stocks, Asbury Automotive Group (ABG), AMN Healthcare Services (AMN), Teck Resources (TECK) and AGCO Corporation (AGCO), which are lucrative value investing opportunities at present.
Henry Schein (HSIC) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends.
Medtronic (MDT) Gains Market Share Despite COVID Headwinds
by Zacks Equity Research
In Respiratory Interventions, despite the year-over-year headwind, as ventilator sales continue to return to pre-pandemic levels, Medtronic (MDT) gains about 400 basis points of share.
Veeva (VEEV) Beats on Q4 Earnings, Narrows '23 Revenue View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both of its segments.
Quidel (QDEL) Rallies 17.4% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Quidel (QDEL) stock rallies on better-than-expected fourth-quarter performance and strong diagnostics portfolio.
Here's Why You Should Invest in AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment.
Masimo's (MASI) SedLine Receives FDA's Pediatric Indication
by Zacks Equity Research
The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.
Insulet (PODD) Product Volume Up, COVID-Led Softness Persists
by Zacks Equity Research
Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.
Henry Schein (HSIC) Expands Data Analytics to Private Practices
by Zacks Equity Research
Henry Schein's (HSIC) introduction of Jarvis Analytics for Private Practices offers practice owners a simple, powerful tool to help improve practice success through data-driven decisions.
Alcon (ALC) Surgical Arm Expands, International Growth Slows
by Zacks Equity Research
In Surgical, Alcon (ALC) remains the market leader in presbyopia correcting IOLs on the strength of both PanOptix and Vivity.
Medtronic's (MDT) NuVent Balloon to Strengthen ENT Business
by Zacks Equity Research
Medtronic's (MDT) Nuvent balloons are one-time use devices featuring a flexible balloon section that allows customized placement based on patient anatomy.
Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss
by Zacks Equity Research
Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on continued growth in its consumer-centric digital solutions.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH